Associations between α-Tocopherol, β-Carotene, and Retinol and Prostate Cancer Survival

Joanne L. Watters,1 Mitchell H. Gail,2 Stephanie J. Weinstein,1 Jarmo Virtamo,1 and Demetrius Albanes2

1Nutritional Epidemiology Branch and Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; and 2Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

Abstract
Previous studies suggest that carotenoids and tocopherols (vitamin E compounds) may be inversely associated with prostate cancer risk, yet little is known about how they affect prostate cancer progression and survival. We investigated whether serum α-tocopherol, β-carotene, and retinol concentrations, or the α-tocopherol and β-carotene trial supplementation, affected survival of men diagnosed with prostate cancer during the α-Tocopherol, β-Carotene Cancer Prevention Study, a randomized, double-blind, placebo-controlled primary prevention trial testing the effects of β-carotene and α-tocopherol supplements on cancer incidence in adult male smokers in southwestern Finland (n = 29,133). Prostate cancer survival was examined using the Kaplan-Meier method with deaths from other causes treated as censoring, and using Cox proportional hazards regression models with hazard ratios (HR) and 95% confidence intervals (CI) adjusted for family history of prostate cancer, age at randomization, benign prostatic hyperplasia, age and stage at diagnosis, height, body mass index, and serum cholesterol. As of April 2005, 1,891 men were diagnosed with prostate cancer and 395 died of their disease. Higher serum α-tocopherol at baseline was associated with improved prostate cancer survival (HR, 0.67; 95% CI, 0.45–1.00), especially among those who had received the α-tocopherol intervention of the trial and who were in the highest quintile of α-tocopherol at baseline (HR, 0.51; 95% CI, 0.20–0.90) or at the 3-year follow-up measurement (HR, 0.26; 95% CI, 0.09–0.71). Serum β-carotene, serum retinol, and supplemental β-carotene had no apparent effects on survival. These findings suggest that higher α-tocopherol (and not β-carotene or retinol) status increases overall prostate cancer survival. Further investigations, possibly including randomized studies, are needed to confirm this observation. [Cancer Res 2009;69(9):3833–41]

Introduction
Although rates vary throughout the world, prostate cancer is the most common cancer diagnosed in the United States, accounting for an estimated 186,320 new cases and 28,660 deaths annually (1). The few well-established risk factors for prostate cancer incidence include increasing age, race/ethnicity (being African American or Jamaican), and having a positive family history (1, 2). Additional factors such as height, physical activity, body mass index (BMI), hormones, and diet are under investigation (2–4). Environmental factors such as diet are thought to be significant contributors as migrants tend to take on the prostate cancer risk profiles of their new country after arriving. In one study of Japanese men who emigrated to Los Angeles, incidence rates were four to nine times higher for the first generation immigrants compared with men living in Japan, and by the second generation, the rates were approximately the same as the general U.S. population (5). Fortunately, 5-year survival is almost 100%, when diagnosed with localized or regional disease, and there are ~2 million prostate cancer survivors in the United States. (1, 6). Yet, little is known about how diet affects prostate cancer progression and survival.

Most studies have investigated diet as an etiologic factor for prostate cancer and a considerable number have focused on carotenoids and tocopherols but with mixed results. Two large cohort studies, NIH-AARP Diet and Health Study and the α-Tocopherol, β-Carotene Cancer Prevention (ATBC) Study, reported protective associations of α-tocopherol with advanced prostate cancer (7, 8), whereas no associations were seen between overall prostate cancer risk and individual carotenoids, retinol, or tocopherols in the European Prospective Investigation Cohort (9) or the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (10). Vitamin E was protective in smokers, as were β-carotene supplements in men with low β-carotene intake, in the Prostate, Lung, Colorectal, and Ovarian trial (10). Currently, several suspected risk factors, such as BMI, soy, fish oil, meat intake, calcium, lycopene, vitamins C and E, and selenium, are also being studied in relation to prostate cancer progression and survival (11–13). However, such research investigating carotenoids and tocopherols is scant. One notable exception came from a cohort of health professionals that examined prediagnostic and postdiagnostic diet and found that consumption of tomato sauce and fish were protective against disease progression, although tocopherols and individual carotenoids were not assessed (14).

Carotenoids and tocopherols (vitamin E) are thought to affect disease risk, progression, and survival through several mechanisms. Carotenoids, the naturally occurring pigments found in many fruits and vegetables, have the antioxidant capacity to quench singlet oxygen and, thus, are thought to prevent conditions related to oxidative stress, such as cardiovascular disease and many cancers (15). Vitamin E consists of four tocopherols and four tocotrienols, of which, α-tocopherol is the most biologically active form in humans and is present in plant and seed oils, nuts, margarine, seeds, and cereal grains. Also an antioxidant, α-tocopherol is hypothesized to prevent cancer by inhibiting formation of carcinogens such as nitrosamines, by decreasing cell proliferation, or by increasing antibody production and enhancing cell-mediated immunity (16).
Materials and Methods

Study population. Data were from the ATBC Study, which was a randomized, double-blind, placebo-controlled primary prevention trial designed to study the effects of β-carotene and α-tocopherol supplements on cancer incidence in 29,133 Caucasian male smokers ages 50 to 69 years in southwestern Finland enrolled between 1985 and 1988 (17). Men who had prior cancer or serious illness or who reported current use of dietary supplements with >20 mg vitamin E, >20,000 IU vitamin A, or >6 mg β-carotene were ineligible. Enrolled men were randomly assigned to one of four groups based on a 2 x 2 factorial design: (a) α-tocopherol (dl-α-tocopherol acetate, 50 mg/d), (b) β-carotene (20 mg/d), (c) both supplements, or (d) placebo capsules for 5 to 8 years until death or trial closure. Although the trial ended on April 30, 1993, on-going follow-up continues through the Finnish Cancer Registry. As of April 30, 2005, there were 1,891 men diagnosed with prostate cancer and 395 deaths due to prostate cancer. The study was approved by the institutional review boards of the U.S. National Cancer Institute and the National Public Health Institute of Finland, and written informed consent was obtained from each participant before randomization.

Case identification. Incident prostate cancer cases (International Classification of Diseases 9, code 185), diagnosed by April 30, 2005 (i.e., up to 20 years follow-up), were identified through the Finnish Cancer Registry, which provides nearly 100% case ascertainment (18). For cases diagnosed through September 2001, the medical records were reviewed centrally by one or two study oncologist(s) for diagnostic confirmation and staging, and cases with available histopathologic or cytologic specimens were reviewed and confirmed by pathologists. Prostate cancer cases diagnosed after September 2001 had only the Finnish Cancer Registry data for site, histology, and date of diagnosis. Advanced cases (n = 397) were defined as those cases with stage III or IV of the tumor-node-metastasis staging system, as defined by the American Joint Committee on Cancer (19). Stage information was only available for those cases diagnosed through September 2001; all cases without stage information were analyzed as a separate missing category. Finland has not adopted population-based prostate-specific antigen screening programs, and only 1 of 246 cases that occurred during the trial period was detected by prostate-specific antigen screening (20). Based on data on the prostate cancers diagnosed by September 2001, we estimate that approximately 10% or fewer of the prostate cancer cases were initially detected through an elevated prostate-specific antigen screen. Deaths were identified from the Register of Causes of Death. Specific causes were derived from the official underlying cause of death.

Data collection. At baseline, study subjects completed general risk factor, smoking, and medical history questionnaires, a food frequency questionnaire of the previous 12 mo, and an exam where height and weight were measured by specially trained registered nurses (21). Participants also provided an overnight fasting serum sample, at baseline and 3 y, that was protected from light and stored at −70°C until it was analyzed for α-tocopherol, β-carotene, and retinol using high-performance liquid chromatography (22). Total and high-density lipoprotein cholesterol concentrations were measured using an enzymatic assay (CHOD-PAP method; Boehringer Mannheim; ref. 23).

Statistical methods. Follow-up time was calculated from the date of diagnosis to the earliest of death from prostate cancer, death from nonprostate cancer causes, and the censoring date (April 30, 2005). Deaths from nonprostate cancer causes were treated as independent censoring events. All men diagnosed with prostate cancer (n = 1,891) were included in

### Table 1. Selected baseline characteristics (means with SDs and proportions) among 1,891 men diagnosed with prostate cancer in the ATBC Study

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Survivors (n = 1,496)</th>
<th>Deceased (n = 395)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at randomization (y)</td>
<td>57.9 ± 5.1</td>
<td>59.6 ± 5.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>70.5 ± 5.4</td>
<td>68.2 ± 6.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Survival (y)</td>
<td>4.1 ± 3.3</td>
<td>3.4 ± 2.8</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.4 ± 3.7</td>
<td>26.3 ± 3.6</td>
<td>0.73</td>
</tr>
<tr>
<td>Cigarettes smoked (per day)</td>
<td>19.8 ± 8.7</td>
<td>19.2 ± 8.7</td>
<td>0.21</td>
</tr>
<tr>
<td>Years of smoking (y)</td>
<td>35.7 ± 8.9</td>
<td>37.6 ± 8.7</td>
<td>0.0002</td>
</tr>
<tr>
<td>Benign prostatic hyperplasia (%)</td>
<td>6</td>
<td>4</td>
<td>0.20</td>
</tr>
<tr>
<td>Prostate cancer family history (%)</td>
<td>6</td>
<td>8</td>
<td>0.17</td>
</tr>
<tr>
<td>Stage at diagnosis (% stage 3 or 4)</td>
<td>21</td>
<td>69</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Missing stage at diagnosis (%)</td>
<td>47</td>
<td>15</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Elected radical surgery (%)</td>
<td>23</td>
<td>4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Physical activity (% active)</td>
<td>21</td>
<td>14</td>
<td>0.005</td>
</tr>
<tr>
<td>Education (% elementary)</td>
<td>71</td>
<td>72</td>
<td>0.35</td>
</tr>
<tr>
<td>Married (% married)</td>
<td>81</td>
<td>83</td>
<td>0.18</td>
</tr>
<tr>
<td>Urban residence (% big town)</td>
<td>46</td>
<td>45</td>
<td>0.85</td>
</tr>
<tr>
<td>Total energy (kcal/d)</td>
<td>2,694 ± 728</td>
<td>2,698 ± 834</td>
<td>0.94</td>
</tr>
<tr>
<td>Intervention group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo (%)</td>
<td>26</td>
<td>26</td>
<td>0.80</td>
</tr>
<tr>
<td>α-Tocopherol only (%)</td>
<td>23</td>
<td>22</td>
<td>0.45</td>
</tr>
<tr>
<td>β-Carotene only (%)</td>
<td>25</td>
<td>31</td>
<td>0.02</td>
</tr>
<tr>
<td>Both (%)</td>
<td>26</td>
<td>22</td>
<td>0.18</td>
</tr>
<tr>
<td>Serum biomarkers at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-Tocopherol (mg/L)</td>
<td>11.9 ± 3.1</td>
<td>11.7 ± 3.1</td>
<td>0.29</td>
</tr>
<tr>
<td>β-Carotene (μg/mL)</td>
<td>221 ± 185</td>
<td>222 ± 185</td>
<td>0.88</td>
</tr>
<tr>
<td>Retinol (μg/mL)</td>
<td>594 ± 130</td>
<td>594 ± 131</td>
<td>0.55</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>6.2 ± 1.1</td>
<td>6.2 ± 1.2</td>
<td>0.87</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol (mmol/L)</td>
<td>1.2 ± 0.3</td>
<td>1.2 ± 0.3</td>
<td>0.80</td>
</tr>
</tbody>
</table>
analyses of baseline serum biomarkers, but only those diagnosed after 3 y (n = 1,557) were included in analyses with serum biomarkers at 3 y. Baseline descriptive characteristics are presented as means (continuous variables) or proportions (categorical variables) for prostate deaths and survivors and compared using Student’s t test or χ² test. Survival was evaluated using Kaplan-Meier survival plots and Cox proportional hazards regression models for each quintile of serum α-tocopherol, β-carotene, and retinol measured at baseline and 3 y. The quintile cut-points, which were estimated from baseline analyte distributions in survivors, were 9.4, 10.9, 12.2, and 14.9 mg/L for α-tocopherol, 104, 155, 210, and 299 μg/L for β-carotene, and 492, 554, 613, and 691 μg/L for retinol. The quintile cut-points used to classify serum α-tocopherol measured 3 y after accrual were 11.5, 13.5, 16.0, and 19.0 mg/L. The proportional hazards assumption was tested by examining Schoenfeld residuals and was upheld in all analyses. Adjusted hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox proportional hazards regression models, adjusted for age at randomization, BMI, age at diagnosis, advanced stage at diagnosis, number of years smoked, and serum cholesterol in α-tocopherol analyses, as it affects bioavailability (24). To account for missing data, we adjusted stage at diagnosis in three categories: (a) before September 2001 and stage I or II, (b) before September 2001 and stage III or IV, and (c) after September 2001 or missing. Additional covariates that were considered but not included were daily number of cigarettes, age at smoking initiation, weight, height, family history of prostate cancer, benign prostatic hyperplasia, physical activity (no activity or light-to-moderate work activity and more than or equal to moderate leisure activity), urban residence, education, marital status, and dietary intakes of protein, fat, polyunsaturated fatty acids, vitamin C, and lycopene. Effect modification was evaluated in stratified multivariate analyses and also tested by adding product interaction terms and comparing P values for the likelihood ratio tests (<0.05) for the models with and without interaction terms. We examined whether the association with survival differed by several factors, including treatment arm, BMI, age at diagnosis, and smoking status.

Table 2. Selected characteristics (means and proportions) of men with prostate cancer by baseline serum α-tocopherol quintile

| Characteristics                        | Q1 (n = 379) | Q2 (n = 378) | Q3 (n = 389) | Q4 (n = 368) | Q5 (n = 377) |
P |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum α-tocopherol quintiles (mg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q1 (4.2–9.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deceased (n = 395; %)</td>
<td>21.9</td>
<td>24.1</td>
<td>19.5</td>
<td>19.3</td>
<td>19.6</td>
</tr>
<tr>
<td>Advanced prostate cancer (%)</td>
<td>36</td>
<td>36</td>
<td>34</td>
<td>34</td>
<td>35</td>
</tr>
<tr>
<td>Missing stage at diagnosis (%)</td>
<td>38.3</td>
<td>39.4</td>
<td>36.8</td>
<td>44.3</td>
<td>41.1</td>
</tr>
<tr>
<td>Age at randomization (y)</td>
<td>59.0</td>
<td>58.5</td>
<td>58.1</td>
<td>57.9</td>
<td>57.8</td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>70.4</td>
<td>70.2</td>
<td>69.7</td>
<td>70.1</td>
<td>69.7</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.6</td>
<td>26.2</td>
<td>26.3</td>
<td>26.5</td>
<td>27.3</td>
</tr>
<tr>
<td>Cigarettes/d</td>
<td>20.3</td>
<td>20.3</td>
<td>19.8</td>
<td>18.8</td>
<td>19.1</td>
</tr>
<tr>
<td>Years of smoking</td>
<td>37.5</td>
<td>36.8</td>
<td>35.2</td>
<td>35.8</td>
<td>35.4</td>
</tr>
<tr>
<td>Benign prostatic hyperplasia (%)</td>
<td>2.9</td>
<td>2.7</td>
<td>2.8</td>
<td>4.6</td>
<td>5.0</td>
</tr>
<tr>
<td>Prostate cancer family history (%)</td>
<td>5.0</td>
<td>7.3</td>
<td>7.3</td>
<td>4.8</td>
<td>5.8</td>
</tr>
<tr>
<td>Physical activity (%) (active)</td>
<td>14.0</td>
<td>18.5</td>
<td>17.2</td>
<td>24.2</td>
<td>23.3</td>
</tr>
<tr>
<td>Education (% elementary)</td>
<td>79.7</td>
<td>74.3</td>
<td>70.2</td>
<td>71.2</td>
<td>63.4</td>
</tr>
<tr>
<td>Married (%)</td>
<td>80.2</td>
<td>78.3</td>
<td>81.5</td>
<td>85.6</td>
<td>85.2</td>
</tr>
<tr>
<td>Urban residence (%)</td>
<td>38.0</td>
<td>46.3</td>
<td>45.5</td>
<td>46.5</td>
<td>51.2</td>
</tr>
<tr>
<td>Elected radical surgery (%)</td>
<td>13.1</td>
<td>17.9</td>
<td>15.4</td>
<td>22.4</td>
<td>17.9</td>
</tr>
<tr>
<td>Dietary intake (daily)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin E (mg)</td>
<td>10.3</td>
<td>11.2</td>
<td>12.0</td>
<td>12.8</td>
<td>14.4</td>
</tr>
<tr>
<td>Zinc (mg)</td>
<td>15.4</td>
<td>15.7</td>
<td>15.5</td>
<td>15.8</td>
<td>16.0</td>
</tr>
<tr>
<td>Vitamin D (μg)</td>
<td>4.5</td>
<td>5.1</td>
<td>5.3</td>
<td>5.4</td>
<td>6.0</td>
</tr>
<tr>
<td>Vitamin C (mg)</td>
<td>89.9</td>
<td>96.7</td>
<td>99.0</td>
<td>107.5</td>
<td>107.4</td>
</tr>
<tr>
<td>Selenium (μg)</td>
<td>88.3</td>
<td>89.4</td>
<td>89.5</td>
<td>90.2</td>
<td>91.8</td>
</tr>
<tr>
<td>Retinol (μg)</td>
<td>1.5</td>
<td>1.6</td>
<td>1.5</td>
<td>1.6</td>
<td>1.6</td>
</tr>
<tr>
<td>Total fat (grams)</td>
<td>125.3</td>
<td>125.3</td>
<td>121.9</td>
<td>122.7</td>
<td>124.1</td>
</tr>
<tr>
<td>Saturated fat (grams)</td>
<td>57.7</td>
<td>55.8</td>
<td>52.1</td>
<td>51.3</td>
<td>49.7</td>
</tr>
<tr>
<td>Polyunsaturated fat (grams)</td>
<td>10.1</td>
<td>10.9</td>
<td>12.0</td>
<td>12.9</td>
<td>15.2</td>
</tr>
<tr>
<td>α-Linolenic acid (mg)</td>
<td>1,487</td>
<td>1,591</td>
<td>1,664.8</td>
<td>1,782.3</td>
<td>1,943.3</td>
</tr>
<tr>
<td>Energy (kcal)</td>
<td>2,736</td>
<td>2,694</td>
<td>2,666</td>
<td>2,672</td>
<td>2,710</td>
</tr>
<tr>
<td>Cholesterol (mg)</td>
<td>588.5</td>
<td>598.6</td>
<td>579.4</td>
<td>573.0</td>
<td>566.0</td>
</tr>
<tr>
<td>α-Tocopherol (mg)</td>
<td>8.9</td>
<td>9.6</td>
<td>10.3</td>
<td>11.0</td>
<td>12.6</td>
</tr>
<tr>
<td>β-Carotene (mg)</td>
<td>1.9</td>
<td>2.0</td>
<td>2.1</td>
<td>2.3</td>
<td>2.3</td>
</tr>
<tr>
<td>Alcohol (grams)</td>
<td>19.5</td>
<td>17.2</td>
<td>16.8</td>
<td>14.6</td>
<td>15.7</td>
</tr>
<tr>
<td>Vegetables (grams)</td>
<td>664.3</td>
<td>684.1</td>
<td>731.1</td>
<td>758.9</td>
<td>778.8</td>
</tr>
<tr>
<td>Fruit (grams)</td>
<td>179.4</td>
<td>194</td>
<td>225.3</td>
<td>231.2</td>
<td>241.9</td>
</tr>
<tr>
<td>Fish (grams)</td>
<td>32.8</td>
<td>39.3</td>
<td>39.6</td>
<td>38.0</td>
<td>41.3</td>
</tr>
<tr>
<td>Serum biomarkers at baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Carotene (μg/mL)</td>
<td>166.8</td>
<td>190.1</td>
<td>229.3</td>
<td>257.5</td>
<td>262.6</td>
</tr>
<tr>
<td>Retinol (μg/mL)</td>
<td>554.7</td>
<td>576.8</td>
<td>582.0</td>
<td>611.1</td>
<td>650.7</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>5.2</td>
<td>5.9</td>
<td>6.2</td>
<td>6.6</td>
<td>7.2</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol (mmol/L)</td>
<td>1.3</td>
<td>1.2</td>
<td>1.2</td>
<td>1.2</td>
<td>1.1</td>
</tr>
</tbody>
</table>
Results

Of the 29,133 men enrolled in the ATBC Study, 1,891 were diagnosed with prostate cancer during 1985 to 2005; 89 of these diagnoses were made within 3 years of accrual. Of the 1,891 with prostate cancer, 395 died from prostate cancer, 527 died from nonprostate cancer causes, and 969 were alive on April 30, 2005. Median follow-up time was 3.4 years (range, 0–15.8) for prostate cancer deaths, compared with 4.1 years (range, 0–17.8) for those who died from other causes or survived through the analysis period (referred to here as “survivors”). Comparisons of baseline characteristics between those with fatal prostate cancer and survivors are presented in Table 1. Overall, survivors were slightly younger upon enrollment (mean, 57.9 versus 59.6 years), older upon diagnosis (mean, 70.5 versus 68.2 years), and had a shorter smoking history (35.7 versus 37.6 years). Survivors were also more likely to be physically active (21% versus 14%), less likely to have advanced prostate cancer at diagnosis (21% versus 69%), more likely to have missing information on stage at diagnosis (47% versus 15%), and also more likely to elect radical surgery (23% versus 4%). In the intervention trial, those with fatal prostate cancer were slightly more likely to have been assigned to the β-carotene only group (31%), but there was no significant difference among the other intervention groups (placebo, α-tocopherol only, or both β-carotene and α-tocopherol). There were also no statistically significant differences in baseline serum nutrient biomarkers between groups.

Table 2 describes demographic, dietary, and biomarker characteristics for each quintile of baseline serum α-tocopherol. Men in the higher quintiles of baseline serum α-tocopherol tended to be more physically active, more likely to live in an urban residence, and have more formal education than those in the lower quintiles. Conversely, most of the self-reported dietary intakes examined were significantly associated with the quintile of baseline serum α-tocopherol. Vitamins C, D, and E, selenium, α-tocopherol, β-carotene, polyunsaturated fat, α-tocopherol, whereas polyunsaturated fat was positively associated with baseline serum α-tocopherol quintiles, whereas saturated fat was inversely associated. Associations were similar for serum α-tocopherol measured at 3 years, although with some attenuation for vitamin C, selenium, and β-carotene (data not shown). Serum baseline concentrations of β-carotene, retinol, and total cholesterol were positively associated with serum baseline concentrations of α-tocopherol, whereas serum high-density lipoprotein cholesterol was inversely associated. Although missing stage at diagnosis and radical surgery election were more likely among survivors in Table 1, there was no association with either factor and quintile of serum α-tocopherol at baseline or 3 years.

Adjusted HRs for prostate cancer mortality were examined by baseline serum α-tocopherol, β-carotene, and retinol (Table 3). Higher baseline serum α-tocopherol was associated with improved prostate cancer survival ($P_{\text{trend}} = 0.03$). Neither serum β-carotene nor retinol had a demonstrable effect. Those with α-tocopherol levels above the second quintile at baseline, which corresponds to concentrations of $\geq 10.9$ mg/L, had a HR of 0.73 (95% CI, 0.57–0.93), which is suggestive of a possible threshold effect. Figure 1A shows

<table>
<thead>
<tr>
<th>Table 3. Adjusted HRs for prostate cancer mortality by baseline serum α-tocopherol, β-carotene, and retinol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Serum α-tocopherol (range mg/L)</td>
</tr>
<tr>
<td>Lowest quintile (&lt;9.4)</td>
</tr>
<tr>
<td>2nd quintile (9.4–10.9)</td>
</tr>
<tr>
<td>3rd quintile (10.9–12.2)</td>
</tr>
<tr>
<td>4th quintile (12.3–14.0)</td>
</tr>
<tr>
<td>5th quintile (&gt;14.0)</td>
</tr>
<tr>
<td>Serum β-carotene (range mg/L)</td>
</tr>
<tr>
<td>Lowest quintile (&lt;105)</td>
</tr>
<tr>
<td>2nd quintile (105–155)</td>
</tr>
<tr>
<td>3rd quintile (156–210)</td>
</tr>
<tr>
<td>4th quintile (211–299)</td>
</tr>
<tr>
<td>5th quintile (&gt;299)</td>
</tr>
<tr>
<td>Serum retinol (range mg/L)</td>
</tr>
<tr>
<td>Lowest quintile (&lt;493)</td>
</tr>
<tr>
<td>2nd quintile (493–554)</td>
</tr>
<tr>
<td>3rd quintile (555–613)</td>
</tr>
<tr>
<td>4th quintile (614–691)</td>
</tr>
<tr>
<td>5th quintile (&gt;691)</td>
</tr>
</tbody>
</table>

NOTE: Adjusted for age at randomization, BMI, age at diagnosis, advanced stage of prostate cancer at diagnosis, years of smoking, and for α-tocopherol, cholesterol.
a comparison of the survival curves for those in the top three quintiles versus those in the bottom two quintiles.

Although there were no statistically significant interactions, there seemed to be a considerable difference in survival by α-tocopherol supplementation status (Table 4). Longer prostate cancer survival was observed for those who received α-tocopherol supplementation (either α-tocopherol only or α-tocopherol and β-carotene combined) and had higher serum α-tocopherol at baseline ($P_{\text{trend}} = 0.04$). The strongest relationship was seen for those who received α-tocopherol supplementation and were in the highest serum α-tocopherol quintile (HR, 0.51; 95% CI, 0.20–0.90). Higher baseline serum β-carotene, regardless of supplementation status, had no effect on prostate cancer survival. We also restricted the analyses to those receiving the single nutrient supplement to assess the whether the combined α-tocopherol and β-carotene supplement acted differently. The overall trend was the same; only those who received α-tocopherol supplements had significantly improved survival with the strongest effect seen for the highest serum α-tocopherol quintile (HR, 0.29; 95% CI, 0.11–0.74).

To examine possible trial effects seen elsewhere (25), survival was also compared by supplementation status and the period of time in which prostate cancer was diagnosed: during the controlled trial (before May 1993), 6-year posttrial follow-up (through April 30, 1999), and through April 30, 2005 (12-year posttrial). The α-tocopherol supplementation death HRs were 0.60 (95% CI, 0.29–1.24) during the trial, 0.71 (95% CI, 0.38–1.30) in the 6-year posttrial period, and 0.98 (95% CI, 0.43–2.25) in the 12-year posttrial period. For β-carotene, the corresponding HRs were 1.02 (95% CI, 0.56–1.84), 0.96 (95% CI, 0.58–1.57), and 1.17 (95% CI, 0.57–2.39).

Prostate cancer survival was examined by quintile of serum α-tocopherol measured 3 years into the study, after the onset of supplementation (Table 5). The results were similar to those for baseline measurements, with higher on-study α-tocopherol levels being related to improved overall survival ($P_{\text{trend}} = 0.12$), particularly for cases in the highest quintile who were receiving the α-tocopherol supplementation (HR, 0.26; 95% CI, 0.09–0.71). However, the highest three quintiles did not have significantly improved prostate cancer survival compared with the bottom two quintiles ($P = 0.52$; Fig. 1B). Compared with a common reference of no α-tocopherol supplementation/lowest serum quintile, the only statistically significant association was poorer survival for those in the lowest quintile and receiving supplementation (HR, 2.82; 95% CI, 1.11–7.15). Although, cases in most other categories experienced increased survival, the interaction test was not significant.

Potential associations between prostate cancer survival and treatment status; BMI; height; smoking status; alcohol use; physical activity; and dietary intake of vitamins C, D, and E, fish, fruits, vegetables, calcium, selenium, lycopene, total carotenoids, α-linolenic acid, and polyunsaturated fat were also examined (data not shown). Overall, none of these associations were statistically significant, but there were trends toward greater prostate cancer survival for men who were taller than 178 cm, with a HR of 0.77 (95% CI, 0.56–1.02), and trends toward poorer survival for men in the highest quartile of pack-years smoked, with HR of 1.30 (95% CI, 0.99–1.72).

**Discussion**

Higher serum and supplemental α-tocopherol seemed to improve overall prostate cancer survival in this investigation. Overall, estimates were similar for the baseline and 3-year serum α-tocopherol determinations, suggesting both dietary and supplemental vitamin E may contribute to improved prostate cancer survival. Baseline serum values reflect dietary intake as men who reported taking supplements above minimum limits upon enrollment were not eligible to participate in the trial, whereas 3-year serum concentrations resulted from dietary intake and the intervention supplementation. The strongest survival associations were seen for men who received α-tocopherol supplementation and had high serum α-tocopherol concentrations at baseline or 3 years, as well as during the first 6 years after the trial supplementation. Neither serum nor supplemental β-carotene or serum retinol had apparent effects on survival.

These findings build upon previous research showing a 41% reduction of prostate cancer mortality in response to α-tocopherol supplementation in the controlled trial component of the ATBC Study from 1985 to 1993 (20). The data presented here included an
additional 12 years of follow-up. Our findings stand in contrast to those recently reported for two large, randomized controlled studies, the Physicians' Health Study (PHS) II and the Selenium and Vitamin E Cancer Prevention Trial (SELECT). PHS II tested vitamins C and E and found no effect of vitamin E supplementation on prostate cancer mortality (HR, 1.01; 95% CI, 0.64–1.58) or incidence (HR, 0.97; 95% CI, 0.85–1.09) after up to 10 years of intervention (26). Similarly, SELECT tested selenium and vitamin E in over 35,000 healthy men and resulted in a nonsignificant increased rate of prostate cancer among the men receiving the supplemental vitamin E (HR, 1.13; 99% CI, 0.95, 1.35) compared with those receiving the vitamin E placebo (27). The dose of vitamin E used in the PHS II was 400 IU synthetic \(\alpha\)-tocopherol every other day, half the effective daily dosage of 400 IU daily all rac-\(\alpha\)-tocopheryl acetate used in SELECT. Several factors could account for these differing results. First, our analysis was based on measured serum \(\alpha\)-tocopherol, whereas PHS II and SELECT tested and reported on their supplementation groups. The intervention dose in the ATBC Study was 50 IU dl-\(\alpha\)-tocopherol acetate per day, 4 to 8 times lower than the other trials and also had a longer period of follow-up (up to 20 years). PHS II and SELECT evaluated much higher dosages for shorter periods and have not yet reported on prospectively measured vitamin E blood levels, which could reveal a different association compared with the high-dose supplementation. Second, PHS II and SELECT were conducted in the United States where prostate-specific antigen testing is common and those enrolled in SELECT were required to undergo prostate cancer screening before study entry in contrast to the ATBC Study. If vitamin E affects advanced prostate cancer in particular, as has been observed (8), then an unscreened population would likely show a stronger beneficial relationship. Third, both recently reported trials were composed of more diverse study populations.

<table>
<thead>
<tr>
<th>Category</th>
<th>No. of cases (no. of deaths)</th>
<th>HR</th>
<th>95% CI</th>
<th>P</th>
<th>(P_{\text{trend}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum (\alpha)-tocopherol (mg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (\alpha)-tocopherol supplement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile</td>
<td>202 (44)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2nd quintile</td>
<td>200 (56)</td>
<td>1.05</td>
<td>(0.70, 1.60)</td>
<td>0.80</td>
<td>0.28</td>
</tr>
<tr>
<td>3rd quintile</td>
<td>214 (38)</td>
<td>0.71</td>
<td>(0.44, 1.16)</td>
<td>0.17</td>
<td>0.95</td>
</tr>
<tr>
<td>4th quintile</td>
<td>170 (35)</td>
<td>0.77</td>
<td>(0.46, 1.29)</td>
<td>0.32</td>
<td>0.90</td>
</tr>
<tr>
<td>5th quintile</td>
<td>201 (49)</td>
<td>0.86</td>
<td>(0.51, 1.47)</td>
<td>0.58</td>
<td>0.02</td>
</tr>
<tr>
<td>(\alpha)-Tocopherol supplement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile</td>
<td>177 (39)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2nd quintile</td>
<td>178 (35)</td>
<td>0.82</td>
<td>(0.50, 1.29)</td>
<td>0.37</td>
<td>0.01</td>
</tr>
<tr>
<td>3rd quintile</td>
<td>175 (38)</td>
<td>0.64</td>
<td>(0.39, 1.04)</td>
<td>0.07</td>
<td>0.01</td>
</tr>
<tr>
<td>4th quintile</td>
<td>198 (36)</td>
<td>0.74</td>
<td>(0.44, 1.23)</td>
<td>0.24</td>
<td>0.02</td>
</tr>
<tr>
<td>5th quintile</td>
<td>176 (25)</td>
<td>0.51</td>
<td>(0.20, 0.90)</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td>Combined</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No supp-lowest quintile</td>
<td>202 (44)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No supp-2nd quintile</td>
<td>200 (56)</td>
<td>0.99</td>
<td>(0.75, 1.30)</td>
<td>0.92</td>
<td>0.01</td>
</tr>
<tr>
<td>No supp-3rd quintile</td>
<td>214 (38)</td>
<td>0.67</td>
<td>(0.50, 0.90)</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>No supp-4th quintile</td>
<td>170 (35)</td>
<td>0.59</td>
<td>(0.43, 0.81)</td>
<td>0.00</td>
<td>0.01</td>
</tr>
<tr>
<td>No supp-5th quintile</td>
<td>201 (49)</td>
<td>0.82</td>
<td>(0.61, 1.10)</td>
<td>0.19</td>
<td>0.01</td>
</tr>
<tr>
<td>Supp-lowest quintile</td>
<td>177 (39)</td>
<td>0.76</td>
<td>(0.58, 1.00)</td>
<td>0.05</td>
<td>0.01</td>
</tr>
<tr>
<td>Supp-2nd quintile</td>
<td>178 (35)</td>
<td>0.69</td>
<td>(0.52, 0.92)</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>Supp-3rd quintile</td>
<td>175 (38)</td>
<td>0.56</td>
<td>(0.41, 0.77)</td>
<td>&lt;0.001</td>
<td>0.01</td>
</tr>
<tr>
<td>Supp-4th quintile</td>
<td>198 (36)</td>
<td>0.63</td>
<td>(0.46, 0.86)</td>
<td>0.004</td>
<td>0.01</td>
</tr>
<tr>
<td>Supp-5th quintile</td>
<td>176 (25)</td>
<td>0.63</td>
<td>(0.44, 0.88)</td>
<td>0.91</td>
<td>0.28</td>
</tr>
<tr>
<td>Serum (\beta)-carotene (mg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (\beta)-carotene supplement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile</td>
<td>193 (46)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2nd quintile</td>
<td>196 (50)</td>
<td>1.10</td>
<td>(0.69, 1.75)</td>
<td>0.69</td>
<td>0.01</td>
</tr>
<tr>
<td>3rd quintile</td>
<td>196 (41)</td>
<td>1.05</td>
<td>(0.65, 1.69)</td>
<td>0.84</td>
<td>0.01</td>
</tr>
<tr>
<td>4th quintile</td>
<td>209 (42)</td>
<td>0.78</td>
<td>(0.43, 1.16)</td>
<td>0.17</td>
<td>0.01</td>
</tr>
<tr>
<td>5th quintile</td>
<td>193 (43)</td>
<td>0.99</td>
<td>(0.62, 1.59)</td>
<td>0.98</td>
<td>0.01</td>
</tr>
<tr>
<td>(\beta)-Carotene supplement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile</td>
<td>188 (31)</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2nd quintile</td>
<td>187 (32)</td>
<td>1.04</td>
<td>(0.68, 1.61)</td>
<td>0.85</td>
<td>0.01</td>
</tr>
<tr>
<td>3rd quintile</td>
<td>176 (35)</td>
<td>1.05</td>
<td>(0.68, 1.63)</td>
<td>0.82</td>
<td>0.01</td>
</tr>
<tr>
<td>4th quintile</td>
<td>169 (32)</td>
<td>0.91</td>
<td>(0.58, 1.40)</td>
<td>0.66</td>
<td>0.01</td>
</tr>
<tr>
<td>5th quintile</td>
<td>184 (43)</td>
<td>1.04</td>
<td>(0.67, 1.60)</td>
<td>0.86</td>
<td>0.01</td>
</tr>
</tbody>
</table>

NOTE: Adjusted for age at randomization, BMI, age at diagnosis, advanced stage of prostate cancer at diagnosis, years of smoking, and for \(\alpha\)-tocopherol, cholesterol.
Abbreviation: Suppl, supplement.
with relatively few smokers compared with the ATBC Study participants. It is possible that the survival benefit of vitamin E is only experienced by smokers.

There are few other studies investigating vitamin E and prostate cancer survival. Two studies included daily vitamin E supplements within their interventions; one found improved survival in combination with ω-3 polyunsaturated fatty acids (27, 28) and another concluded that a vegan diet with soy, fish oil, and several micronutrient supplements delayed disease progression (29). Although each study showed sizable effects, it is not possible to distinguish the contribution of supplemental vitamin E from the other dietary intervention components. However, dietary agents have been shown to affect prostate cancer survival. An investigation within the Health Professionals Follow-up Study examined prediagnostic and postdiagnostic diet and found high intake of tomato sauce (HR, 0.56; 95% CI, 0.38–0.82) and fish (HR, 0.73; 95% CI, 0.52–1.02) were protective against disease progression (14). As prostate cancer is a disease with relatively good survival, there is interest in other causes of death in men diagnosed with prostate cancer. We found a trend toward protection for all-cause mortality (including prostate cancer; HR, 0.67; 95% CI, 0.52–0.87 for highest versus lowest quintile; \( P_{\text{trend}} = 0.01 \), which was slightly attenuated when those who died of prostate cancer were excluded (HR, 0.70; 95% CI, 0.46–0.98 for highest versus lowest quintile; \( P_{\text{trend}} = 0.11 \)), suggesting a possible effect for α-tocopherol on other causes of death in men with prostate cancer. Although meta-analyses suggest vitamin E has no effect on all-cause mortality (30), lower mortality rates were observed for men with higher serum vitamin E at baseline in another analysis within the ATBC data (31).

There is considerably more evidence available for the relationship between vitamin E and prostate cancer risk than for survival. Several, but not all, observational and intervention studies have shown a strong inverse association between α-tocopherol and the risk of developing prostate cancer, particularly for advanced cancers or among smokers (32). For example, analysis from the Prostate, Lung, Colorectal, and Ovarian trial found no association

<table>
<thead>
<tr>
<th>Category</th>
<th>No. of cases (no. of deaths)</th>
<th>HR</th>
<th>95% CI</th>
<th>( P )</th>
<th>( P_{\text{trend}} )</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Serum α-tocopherol (range mg/L)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile (&lt;11.5)</td>
<td>315 (66)</td>
<td>1</td>
<td>(0.68, 1.36)</td>
<td>0.83</td>
<td></td>
</tr>
<tr>
<td>2nd quintile (11.5–13.4)</td>
<td>301 (60)</td>
<td>0.96</td>
<td>(0.67, 1.30)</td>
<td>0.68</td>
<td></td>
</tr>
<tr>
<td>3rd quintile (13.5–16.0)</td>
<td>341 (78)</td>
<td>0.93</td>
<td>(0.50, 1.09)</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>4th quintile (16.1–19.0)</td>
<td>295 (44)</td>
<td>0.74</td>
<td>(0.54, 1.17)</td>
<td>0.24</td>
<td>0.12</td>
</tr>
<tr>
<td>5th quintile (&gt;19.0)</td>
<td>305 (55)</td>
<td>0.80</td>
<td>(0.54, 1.17)</td>
<td>0.24</td>
<td>0.12</td>
</tr>
<tr>
<td>No α-tocopherol supplement</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile</td>
<td>289 (61)</td>
<td>1</td>
<td>(0.65, 1.45)</td>
<td>0.90</td>
<td></td>
</tr>
<tr>
<td>2nd quintile</td>
<td>228 (44)</td>
<td>0.97</td>
<td>(0.61, 1.49)</td>
<td>0.83</td>
<td></td>
</tr>
<tr>
<td>3rd quintile</td>
<td>172 (39)</td>
<td>0.95</td>
<td>(0.45, 1.63)</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>4th quintile</td>
<td>74 (13)</td>
<td>0.85</td>
<td>(0.38, 1.69)</td>
<td>0.56</td>
<td>0.52</td>
</tr>
<tr>
<td>5th quintile</td>
<td>40 (8)</td>
<td>0.80</td>
<td>(0.38, 1.69)</td>
<td>0.56</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>α-Tocopherol supplement</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest quintile</td>
<td>26 (5)</td>
<td>1</td>
<td>(0.15, 1.14)</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td>2nd quintile</td>
<td>73 (16)</td>
<td>0.41</td>
<td>(0.14, 0.94)</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>3rd quintile</td>
<td>169 (39)</td>
<td>0.36</td>
<td>(0.14, 0.94)</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>4th quintile</td>
<td>221 (31)</td>
<td>0.24</td>
<td>(0.09, 0.64)</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>5th quintile</td>
<td>265 (47)</td>
<td>0.26</td>
<td>(0.09, 0.71)</td>
<td>0.01</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Combined</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No supp-lowest quintile</td>
<td>289 (61)</td>
<td>1</td>
<td>(0.62, 1.39)</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>No supp-2nd quintile</td>
<td>228 (44)</td>
<td>0.93</td>
<td>(0.57, 1.34)</td>
<td>0.53</td>
<td></td>
</tr>
<tr>
<td>No supp-3rd quintile</td>
<td>172 (39)</td>
<td>0.87</td>
<td>(0.31, 1.43)</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>No supp-4th quintile</td>
<td>74 (13)</td>
<td>0.95</td>
<td>(0.50, 1.82)</td>
<td>0.88</td>
<td></td>
</tr>
<tr>
<td>No supp-5th quintile</td>
<td>40 (8)</td>
<td>0.67</td>
<td>(0.31, 1.43)</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>Supp-lowest quintile</td>
<td>26 (5)</td>
<td>2.82</td>
<td>(1.11, 7.15)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Supp-2nd quintile</td>
<td>73 (16)</td>
<td>1.27</td>
<td>(0.73, 2.21)</td>
<td>0.40</td>
<td></td>
</tr>
<tr>
<td>Supp-3rd quintile</td>
<td>169 (39)</td>
<td>1.08</td>
<td>(0.71, 1.62)</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>Supp-4th quintile</td>
<td>221 (31)</td>
<td>0.80</td>
<td>(0.51, 1.24)</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>Supp-5th quintile</td>
<td>265 (47)</td>
<td>0.84</td>
<td>(0.55, 1.27)</td>
<td>0.40</td>
<td>0.24</td>
</tr>
<tr>
<td><em><em>Combined quintiles</em> (range mg/L)</em>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No supp-1st &amp; 2nd quintile (≤13.5)</td>
<td>517 (105)</td>
<td>1</td>
<td>(0.64, 1.27)</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>No supp-3rd–5th quintile (≤13.5)</td>
<td>286 (60)</td>
<td>0.90</td>
<td>(0.64, 1.27)</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>Supp-1st &amp; 2nd quintile (≤13.5)</td>
<td>99 (21)</td>
<td>1.48</td>
<td>(0.92, 2.39)</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>Supp-3rd–5th quintile (≤13.5)</td>
<td>655 (117)</td>
<td>0.93</td>
<td>(0.71, 1.22)</td>
<td>0.59</td>
<td>0.81</td>
</tr>
</tbody>
</table>

NOTE: Adjusted for age at randomization, BMI, age at diagnosis, advanced stage of prostate cancer at diagnosis, years of smoking, and for α-tocopherol, cholesterol.

*Men in 1st and 2nd quintiles of serum α-tocopherol were compared with those in the 3rd to 5th quintiles. The value between 2nd and 3rd quintile of serum α-tocopherol at 3 y was 13.5 mg/L.
with risk in the general population, but vitamin E was strongly protective in smokers (relative risk, 0.29; 95% CI, 0.12–0.68; ref. 10). Similar work using the ATBC Study with 19 years of follow-up found that serum α-tocopherol was associated with reduced risk of prostate cancer (relative risk, 0.80; 95% CI, 0.66–0.96 for highest versus lowest quintile), especially advanced disease (relative risk, 0.56; 95% CI, 0.36–0.85; ref. 8), whereas the original effect seen in the trial period of the study was a 32% reduction in prostate cancer risk with α-tocopherol supplementation (20). New observational studies are needed to tease apart the relationship between prostate cancer risk and α-tocopherol from supplementation versus serum levels as well as the possible interactions with smoking. Similar investigations are needed to determine the role of nutritional factors in prostate cancer survival.

The mechanisms through which vitamin E might affect the development and progression of prostate cancer are not fully understood; however, a number of biologically plausible pathways have been suggested. α-Tocopherol is thought to affect carcinogenesis by detoxifying oxidizing radicals via its antioxidant properties, inducing cell cycle arrest in prostate cancer cells (33), decreasing cell growth by down-regulating the phosphoinositide 3-kinase pathway (34), enhancing cell-mediated immunity (16), targeting transcription factors, such as nuclear factor-κB, that contribute to malignant transformation and cell growth (35), and decreasing serum androgen concentrations (36). Many of these biological actions are likely to be involved in prostate cancer survival.

Prostate cancer survival was greater for men with baseline serum α-tocopherol of ≥11 mg/L, regardless of supplementation status, but there was slightly better survival for those receiving the vitamin E supplementation (HR, 0.51; 95% CI, 0.27–0.96). Similar results were seen after 3 years among those in the highest α-tocopherol quintiles who received supplementation had considerably better survival (HR, 0.29–95% CI, 0.10–0.82). Vitamin E supplementation has been associated with decreased prostate cancer risk in several cohort studies, which reflects self-selected supplement use rather than randomized assignment in an intervention trial. Long-term (10 years average) supplement use of vitamin E (≥400 IU) was associated with the reduced risk of advanced prostate cancers (HR, 0.43; 95% CI, 0.19–1.00) in the VITamins And Lifestyle cohort study (37). A similar nonsignificant trend was seen for advanced cases in nonsmokers but not current or former smokers in the NIH-AARP Diet and Health Study, a large cohort study of men ages 50 to 71 years; however, supplemental vitamin E intake was unrelated to prostate cancer risk in the total population (7). Other recent analyses suggest possible harm from vitamin E intake, but there was a lack of association with stage and period of diagnosis in the Physicians Health Study (relative risk, 1.0; 95% CI, 0.9–1.1; ref. 45), a randomized trial of aspirin and 50 mg β-carotene on alternate days, but β-carotene was not associated with an increased risk of aggressive prostate cancer in a nested case-control study using data from the Prostate, Lung, Colorectal, and Ovarian Trial (relative risk, 1.67; 95% CI, 1.03–2.72; ref. 46).

There are several notable strengths of this study. The availability of a large number of prostate cancer cases with considerable postdiagnosis follow-up provided substantial power to detect potential associations with survival that may have been obscured in smaller studies. The use of serum nutrient biomarkers reduces the measurement error associated with self-reported data for dietary and supplement intake. Participants were exceptionally adherent during the trial period, with 96% of supplement capsules taken as scheduled, and there was no off-trial supplement use reported. Finally, because prostate-specific antigen screening was not widely used at the time of the ATBC trial, the potential for lead-time bias caused by overdiagnosis of cancers that are not clinically relevant was low.

Limitations of the study include its being conducted in a relatively homogeneous cohort of male Finnish smokers, which limits the generalizability of our findings to nonsmokers and other races and ethnicities. We did not have comprehensive data concerning prostate cancer treatment; however, surgery was distributed equally across categories of serum α-tocopherol (baseline and 3 years) and supplementation status among those who died of prostate cancer. Another limitation was lack of detailed data on stage and grade of prostate cancer in those diagnosed after September 2001. However, cross-tabulations of α-tocopherol levels by stage in those diagnosed at or before September 2001 failed to reveal a correlation of α-tocopherol levels with stage. Thus, stage is unlikely to confound our results. Moreover, we adjusted stage and period of diagnosis in three categories [(a) before September 2001 and stage I or II, (b) before September 2001 and stage III or IV, and (c) after September 2001 or missing]. Gleason score, a strong predictor of survival, was available only for cases diagnosed before May 1, 1993 (<10% of cases), and thus, not included in these analyses. An examination of available data showed that Gleason score was strongly associated with survival as expected but was not associated with serum α-tocopherol or β-carotene at either baseline or 3 years reducing concerns about potential confounding. We did not have information on serum levels or diet after 3 years on-study or posttrial supplement use; thus, changes in diet or supplement use could have resulted in misclassification that would have biased our results to toward the null. This was an observational study of prostate cancer cases,
although it was conducted within the ATBC cohort for a randomized trial. Thus, we cannot exclude the possibility of residual confounding by unmeasured or unknown characteristics, especially clinicopathologic factors that may be related to survival, although we adjusted for a number of potential confounders.

In summary, our results suggest dietary and supplemental α-tocopherol may improve prostate cancer survival. Data from similar studies in other populations would be useful. Considering the large number of men diagnosed with prostate cancer, such nutritional modifications could have a significant effect if subsequent randomized trials in men with newly diagnosed prostate cancer prove a benefit.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
Received 12/5/08; revised 2/9/09; accepted 2/24/09; published OnlineFirst 4/21/09.

Grant Support: Intramural Research Program of the NIH and the National Cancer Institute. Additionally, this research was supported by USPHS contracts N01-CN-45165, N01-RC-45035, and N01-RC-37004 from the National Cancer Institute, Department of Health and Human Services.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References


Associations between α-Tocopherol, β-Carotene, and Retinol and Prostate Cancer Survival

Joanne L. Watters, Mitchell H. Gail, Stephanie J. Weinstein, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-08-4640

Cited articles
This article cites 41 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/9/3833.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/69/9/3833.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/69/9/3833.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.